Borderline gastrointestinal stromal tumors:clinical and pathological studies of 279 cases

LIU Ya-lan,XU Chen,HOU Ying-yong,LU Shao-hua,XU Jian-fang,JI Yuan,HOU Jun,ZENG Hai-ying,TAN Yun-shan,ZHU Xiong-zeng
2011-01-01
Abstract:Purpose Borderline gastrointestinal stromal tumors(GISTs) are intermediate tumors between benign and malignant variants;however,the clinical and pathological features of borderline GISTs remain poorly defined.The present study was aimed to characterize borderline GISTs and to re-evaluate the NIH consensus criteria that are often used to classify GISTs.Methods Medical records and specimens were retrospectively examined in 840 cases of GISTs.485 and 76 patients with any of the parameters predictive of either malignant or benign GISTs,respectively,were excluded.Results Among the remaining 279 borderline GIST patients,223 were followed for 1 to 31 years.Two patients developed local recurrence,and both were cured by subsequent surgical removal alone.The 5-year disease-free survival and overall survival rates were 99% and 100%,respectively.Morphologically,borderline GISTs typically exhibited moderate cellularity,and subsets of them also showed moderate atypia,low mitotic activities,or a large tumor in size.According to the NIH consensus criteria,the risk levels of these 279 GISTs were classified into very low to high.However,the disease-free survival rates were not significantly different among all these risk groups(P=0.681).Conclusions Borderline GISTs display intermediate clinical and morphological features distinct from benign and malignant GISTs.Some borderline GISTs show malignant potential,and these patients may require long-term follow-up.The NIH criteria,primarily based on tumor size and mitotic count,are not suitable to evaluate the biological behaviors of borderline GISTs.
What problem does this paper attempt to address?